GeneHealth - Your precision medicine

Cholinergic Urticaria

Disease Details

Family Health Simplified

Buy Membership

Description: Cholinergic urticaria is a type of physical urticaria (hives) triggered by an increase in body temperature, leading to small, itchy welts on the skin.
Type: Cholinergic urticaria is not generally classified as a genetic disorder; it is a type of physical urticaria or hives triggered by an increase in body temperature, such as during exercise, hot showers, or stress. There is no specific type of genetic transmission associated with cholinergic urticaria.
Signs And Symptoms: **Signs and Symptoms of Cholinergic Urticaria:**

1. **Small, Raised Bumps (Wheals):** These typically appear on the skin shortly after exposure to heat or sweating. The bumps are small and may be surrounded by a red flare.

2. **Itching or Prickling Sensation:** Often accompanies the appearance of the wheals, causing significant discomfort.

3. **Redness:** The areas affected by the wheals can become red and inflamed.

4. **Triggered by Heat or Sweating:** Symptoms usually occur during or after physical exercise, hot baths, emotional stress, or consumption of hot or spicy foods.

5. **Short Duration:** The wheals and associated symptoms commonly last for 30 minutes to an hour but can sometimes persist for longer.

6. **Possible Systemic Symptoms:** In some cases, individuals may experience systemic reactions such as headaches, dizziness, or shortness of breath, although these are less common.

Cholinergic urticaria primarily results from the body’s response to a rise in core temperature, leading to the characteristic skin symptoms due to an exaggerated cholinergic response.
Prognosis: Cholinergic urticaria is a type of physical urticaria triggered by heat, exercise, or stress, leading to small, itchy hives. The prognosis for cholinergic urticaria varies among individuals. Some may experience symptoms periodically for months or years, while others may see an improvement or complete resolution of symptoms over time. Proper management, which can include avoiding triggers, using antihistamines, and other treatments, can improve quality of life.
Onset: Cholinergic urticaria typically has an onset during adolescence or early adulthood, though it can occur at any age. The term "nan" does not apply here.
Prevalence: The prevalence of cholinergic urticaria is not precisely known, as it is not one of the most commonly studied forms of urticaria. However, it is considered to be relatively uncommon. Estimates suggest that it affects a small percentage of the population, often manifesting in young adults and typically more prevalent in males.
Epidemiology: Cholinergic urticaria is a type of physical urticaria (hives) triggered by an increase in body temperature. It most commonly affects young adults and adolescents. The prevalence is higher in males compared to females. Cholinergic urticaria is relatively rare but often underdiagnosed. The exact prevalence is difficult to determine due to these underdiagnoses and variability in severity of symptoms among individuals.
Intractability: Cholinergic urticaria is generally not considered intractable. Many patients respond to treatments such as antihistamines, lifestyle modifications, or avoidance of known triggers, such as heat, exercise, or stress. However, the condition can be chronic and may require ongoing management. In some cases, additional treatments like immunomodulatory therapies might be needed for more severe forms.
Disease Severity: Cholinergic urticaria is generally not considered life-threatening, but the severity can vary among individuals. Some may experience mild symptoms like small, itchy hives during physical activity or in warm environments, while others might encounter more intense symptoms, including larger hives, significant discomfort, and, in rare cases, anaphylactic reactions.
Healthcare Professionals: Disease Ontology ID - DOID:14443
Pathophysiology: The wheals, hypohidrosis, and pain seems to result from the low expression levels of acetylcholinesterase (AchE) and cholinergic receptor, muscarinic 3 (CHRM3) in the eccrine gland epithelial cells.
Elevated expression levels of CCL2/MCP-1, CCL5/RANTES and CCL17/TARC which result in chemoattracted CD4+ and CD8+ T cell populations to the surrounding area may be responsible for exerting a downmodulatory effect on the AchE and CHRM3 expressions.
Corticosteroid inhibits the expressions of CCL2/MCP-1, CCL5/RANTES and CCL17/TARC. This further support the notion that CCL2/MCP-1, CCL5/RANTES and CCL17/TARC play a crucial role.
Carrier Status: Cholinergic urticaria is not a genetic disorder, so there is no carrier status associated with it.
Mechanism: Cholinergic urticaria (ChU) is a type of physical urticaria characterized by the development of itchy hives or wheals upon an increase in body temperature, such as from exercise, hot showers, or emotional stress.

**Mechanism:**
1. **Triggering Factors**: Increased body temperature from activities like exercise or hot baths.
2. **Sympathetic Nervous System Activation**: This leads to higher levels of acetylcholine, a neurotransmitter.
3. **Acetylcholine Action**: Acetylcholine binds to muscarinic receptors on the surface of skin cells.
4. **Mast Cell Activation**: Binding of acetylcholine causes the release of histamine from mast cells.
5. **Inflammatory Response**: The release of histamine leads to vasodilation, increased vascular permeability, and wheal-and-flare reactions typical of hives.

**Molecular Mechanisms:**
1. **Acetylcholine-Mediated Pathways**:
- **Muscarinic Receptors**: Specifically, the M3 muscarinic receptors on mast cells and sweat glands are believed to play a role.
- **Upregulation of cAMP**: Activation of adenylate cyclase by acetylcholine increases cyclic AMP (cAMP) levels, which is part of the pathway leading to mast cell degranulation.

2. **Histamine Release**:
- **Histamine Receptors**: Once released, histamine acts via H1 and H2 receptors on endothelial cells, increasing vascular permeability and leading to the characteristic swelling and redness of hives.

3. **Cytokine and Chemokine Involvement**:
- Cytokines such as IL-4, IL-5, and TNF-α may be upregulated during mast cell degranulation, contributing to the inflammatory response and recruitment of additional immune cells.

4. **Cholinergic Pathway Adaptations**:
- Chronic exposure to heat or stress can lead to desensitization or hypersensitivity of muscarinic receptors, influencing the severity and frequency of urticaria episodes.

Understanding these mechanisms can aid in better targeting treatments such as antihistamines, anticholinergics, or other therapeutic approaches.
Treatment: First-line treatment: H1RAs are first-line therapy for patients with CholU, but many patients show only a mild to moderate response to standard H1RA doses. The addition of an H2RA was reported to be effective in patients with refractory CholU that was unresponsive to up-dosing of an H1RA. Other studies have demonstrated the efficacy of scopolamine butylbromide (an anticholinergic agent); combinations of propranolol (a b2-adrenergic blocker), antihistamines, and montelukast; and treatment and injection with botulinum toxin.
Non-pharmacological treatment: In the absence of sweat, cold-water sprays and wet towels can be used to increase the evaporative loss of heat from the skin. Shifting to a cooler or air-conditioned environments when necessary can also reduce discomfort. In the event of severe hyperthermia (body temperature >106 °F/41 °C), drastic measures such as immersion in ice-cold water are necessary to prevent irreversible brain damage.
Compassionate Use Treatment: Cholinergic urticaria, a type of physical urticaria triggered by heat or sweat, may benefit from various treatment options.

**Compassionate Use Treatments:**
- Compassionate use generally involves experimental or off-label therapies not readily available. Official compassionate use programs may offer access to specific, investigational treatments if conventional therapies fail.

**Off-Label or Experimental Treatments:**
1. **Omalizumab (Xolair)**: Originally approved for chronic idiopathic urticaria and asthma, it has shown promise in case reports and small studies for cholinergic urticaria.
2. **Antihistamines**: While first-line treatments, higher doses or combinations of H1 and H2 antihistamines beyond typical prescriptions may be considered off-label.
3. **Anticholinergic agents**: Medications such as glycopyrrolate and clonidine, although primarily indicated for other conditions, have been explored for effectiveness in reducing symptoms by decreasing sweating.
4. **Monoclonal antibodies**: There are ongoing research and trials investigating new biological agents targeting specific pathways involved in cholinergic urticaria.

For any treatments, close coordination with a healthcare provider is essential to monitor effectiveness and adverse effects. Always consult a medical professional before considering off-label or experimental options.
Lifestyle Recommendations: For cholinergic urticaria, lifestyle recommendations include:

1. **Avoid Triggers**: Identify and avoid activities or situations that trigger sweating, such as hot showers, spicy foods, exercise, or emotional stress.

2. **Temperature Management**: Stay in cool environments to minimize sweating and overheating.

3. **Gradual Exposure**: Gradually increase tolerance to heat and exercise through controlled and progressive exposure.

4. **Stress Management**: Practice stress-reduction techniques such as meditation, yoga, or deep-breathing exercises to help prevent flare-ups.

5. **Wear Breathable Clothing**: Opt for loose, breathable, and moisture-wicking fabrics to reduce skin irritation and overheating.

6. **Healthy Diet**: Maintain a balanced diet to keep your body healthy and potentially reduce the severity of outbreaks.

7. **Hydration**: Stay well-hydrated to help regulate body temperature.

8. **Antihistamines**: Consult with a healthcare provider about taking antihistamines before engaging in activities that typically cause hives.
Medication: Cholinergic urticaria, also known as heat hives, can be managed with various medications, including:

1. **Antihistamines**:
- Non-sedating antihistamines such as cetirizine, loratadine, or fexofenadine.
- Sedating antihistamines like diphenhydramine or hydroxyzine for severe cases.

2. **H2 antagonists**:
- Ranitidine or famotidine may be added if antihistamines alone are not effective.

3. **Omalizumab**:
- This is a monoclonal antibody used in some chronic cases that do not respond to traditional treatments.

4. **Anticholinergic agents**:
- Such as glycopyrrolate in severe cases to reduce sweating and subsequent hive formation.

Always consult a healthcare professional before starting or changing medications for cholinergic urticaria.
Repurposable Drugs: Cholinergic urticaria is a type of hives triggered by an increase in body temperature, often due to exercise, hot showers, or stress. There are no widely recognized drugs specifically repurposed exclusively for cholinergic urticaria, but several medications used for other conditions have shown efficacy in managing symptoms:

1. **Antihistamines:** Commonly used to reduce hives and itching. Examples include cetirizine, loratadine, and fexofenadine.
2. **H2 Antagonists:** Sometimes used in combination with antihistamines to enhance effectiveness. Examples include ranitidine and famotidine.
3. **Leukotriene Receptor Antagonists:** Medications such as montelukast may be used, especially if antihistamines alone are insufficient.
4. **Beta-Blockers:** Propranolol has been mentioned in literature for off-label use in reducing the severity of symptoms in some cases.
5. **Omalizumab:** Although typically used for chronic idiopathic urticaria, it may be considered in refractory cases of cholinergic urticaria.

Always consult a healthcare provider for personalized medical advice and treatment options.
Metabolites: Cholinergic urticaria is a type of physical urticaria induced by an increase in body temperature, leading to small, itchy hives. There is no direct association with specific metabolites that are characteristic of cholinergic urticaria. The condition is primarily related to the activation of the cholinergic nervous system, leading to the release of acetylcholine, which then triggers the mast cells to release histamine and other inflammatory mediators.
Nutraceuticals: There is no well-established evidence suggesting that specific nutraceuticals are effective in treating cholinergic urticaria, which is a type of heat-induced hives. Management typically involves avoiding triggers, antihistamines, and other medications as prescribed by a healthcare provider.
Peptides: Cholinergic urticaria (CHU) is a type of physical urticaria triggered by an increase in body temperature, often due to exercise, hot showers, or emotional stress. It is often characterized by small, intensely itchy hives.

The term "peptides" in the context of cholinergic urticaria is not directly relevant unless you are referring to the possible involvement of neurotransmitters or other bioactive peptides influencing the condition. Acetylcholine, a neurotransmitter, plays a significant role in CHU as it is involved in the activation of sweat glands, which can trigger symptoms.

"NAN" does not directly relate to any known concept in the context of cholinergic urticaria or its treatment. If "NAN" was intended to refer to a specific term or abbreviation, please provide additional context for a more accurate explanation.